---
title: "Neurocrine Biosciences Q4 earnings: EPS $1.88 missed by -10.05%, revenue up $177.80M YoY. Details on Benzinga.com."
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275660582.md"
description: "Neurocrine Biosciences (NASDAQ: NBIX) released its Q4 financial results on February 11, 2026, at 04:01 PM. The earnings report showed that the company fell short of estimated earnings by -10.05%, with an EPS of $1.88 compared to the expected $2.09. Revenue saw an increase of $177.80 million compared to the previous year. In terms of past earnings performance, the company surpassed expectations on EPS. For more detailed information, the full story can be found on Benzinga.com."
datetime: "2026-02-11T21:11:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275660582.md)
  - [en](https://longbridge.com/en/news/275660582.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275660582.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275660582.md) | [English](https://longbridge.com/en/news/275660582.md)


# Neurocrine Biosciences Q4 earnings: EPS $1.88 missed by -10.05%, revenue up $177.80M YoY. Details on Benzinga.com.

Neurocrine Biosciences (NASDAQ: NBIX) released its Q4 financial results on February 11, 2026, at 04:01 PM. The earnings report showed that the company fell short of estimated earnings by -10.05%, with an EPS of $1.88 compared to the expected $2.09. Revenue saw an increase of $177.80 million compared to the previous year. In terms of past earnings performance, the company surpassed expectations on EPS. For more detailed information, the full story can be found on Benzinga.com.

### 相關股票

- [Neurocrine Biosciences (NBIX.US)](https://longbridge.com/zh-HK/quote/NBIX.US.md)

## 相關資訊與研究

- [Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX](https://longbridge.com/zh-HK/news/281706200.md)
- [A Look At Neurocrine Biosciences (NBIX) Valuation After New INGREZZA Data In Older Tardive Dyskinesia Patients](https://longbridge.com/zh-HK/news/281593054.md)
- [Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings | NBIX Stock News](https://longbridge.com/zh-HK/news/280629770.md)
- [Neurocrine Biosciences CEO Kyle Gano Reports Disposal of Common Shares](https://longbridge.com/zh-HK/news/273146859.md)
- [Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday](https://longbridge.com/zh-HK/news/274766673.md)